Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Pipeline overview and development strategy

• Four clinical programs in development, with ADG126 (masked anti-CTLA-4) as the lead candidate in phase 2 trials for MSS CRC in combination with Keytruda.

• Focus on potent and toxic targets, including CD3-binding T-cell engagers, leveraging proprietary NEObody, SAFEbody, and POWERbody platforms.

• Pipeline designed to address fundamental pathways in cancer and autoimmune diseases, aiming for both efficacy and safety.

Clinical data highlights and differentiation

• ADG126 demonstrates a wide therapeutic window, allowing dosing up to 20 mg/kg, significantly higher than current therapies.

• Early data show significant tumor reduction and stable disease in MSS CRC, with confirmed partial responses and promising PFS and OS outcomes.

• Safety profile of ADG126 plus pembro is comparable to pembro monotherapy, enabling potential combinations with standard therapies.

• Upcoming ESMO updates will provide mature OS and PFS data for different dosing regimens.

Additional programs and partnerships

• ADG206, a 4-1BB agonist, shows no dose-limiting toxicity up to 6 mg/kg, with enhanced potency over previous candidates.

• T-cell engager candidates using SAFEbody technology achieve high dosing and complete B-cell depletion in preclinical models, with favorable safety and PK profiles.

• Multiple collaborations with global pharma partners, including Sanofi and Roche, are ongoing and expanding.